Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cornelia Liedtke"'
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
A. Kohls, Hans-Peter Fischer, Ronald E. Kates, Matthias Christgen, Michael Braun, T. Reimer, Hans Heinrich Kreipe, Nadia Harbeck, Jochem Potenberg, Katja Krauss, E-M. Grischke, Andrea Stefek, Helmut Forstbauer, O Gluz, Doris Augustin, Ulrike Nitz, Claudia Schumacher, Johannes Schumacher, Cornelia Liedtke, Sherko Kuemmel, Rachel Wuerstlein
Publikováno v:
Annals of Oncology. 28:2768-2772
Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR- trial assessed whether patients with stro
Autor:
Birgit Pott, Markus Wallwiener, Johannes Ettl, Rüdiger Schulz-Wendtland, Leyla Akpolat-Basci, Erik Belleville, Alexander Hein, Diana Lüftner, Florin-Andrei Taran, Dirk Pott, Peyman Hadji, Wolfgang Janni, Hans Tesch, Naiba Nabieva, Andreas Schneeweiss, Hans-Christian Kolberg, Thomas Geyer, Hanna Einarson, Michael P. Lux, Bernhard Volz, Andreas D. Hartkopf, Michael Untch, Lothar Häberle, Cornelia Liedtke, Volkmar Müller, Sarah Wetzig, Peter A. Fasching, Harald Seeger, Diethelm Wallwiener, Sara Y. Brucker, Friedrich Overkamp, Arndt Hartmann, Matthias W. Beckmann, Tanja Fehm, Paul Gass
Publikováno v:
Breast cancer research and treatment. 173(2)
Neoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM).
Autor:
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Nikola Bangemann, Christoph Lindner, Sherko Kuemmel, Michael Clemens, Jochem Potenberg, Peter Staib, Andreas Kohls, Raquel von Schumann, Ronald Kates, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck
Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590677f09768f30013068e57eb5b3aae
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85053498560
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85053498560
Autor:
S. Loibl, Joyce Bischoff, Thomas Karn, Yasmin Issa-Nummer, Christian Schem, I. Meinhold-Heerlein, Maik Hauschild, Brigitte Rack, Volkmar Müller, C. zu Eulenburg, Michael Untch, F Khandan, H. Eidtmann, Peter A. Fasching, Sabine Schmatloch, J Huober, Christine Mau, Cornelia Liedtke, G. von Minckwitz, Tanja Fehm, Isabell Witzel
Publikováno v:
British Journal of Cancer
Background: We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is stil
Autor:
Philip C, Schouten, Oleg, Gluz, Nadia, Harbeck, Svjetlana, Mohrmann, Raihana, Diallo-Danebrock, Enrico, Pelz, Janneke, Kruizinga, Arno, Velds, Marja, Nieuwland, Ron M, Kerkhoven, Cornelia, Liedtke, Markus, Frick, Ronald, Kates, Sabine C, Linn, Ulrike, Nitz, Frederik, Marme
Publikováno v:
International journal of cancer. 139(4)
BRCA1 is an important protein in the repair of DNA double strand breaks (DSBs), which are induced by alkylating chemotherapy. A BRCA1-like DNA copy number signature derived from tumors with a BRCA1 mutation is indicative for impaired BRCA1 function a
Autor:
Sao Jiralerspong, Funda Meric-Bernstam, Shana L. Palla, Chad M. Barnett, Cornelia Liedtke, Limin Hsu, Sharon H. Giordano, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Mien Chie Hung
Publikováno v:
Journal of Clinical Oncology. 27:3297-3302
Purpose Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support t
Autor:
Henry Mark Kuerer, Christos Sotiriou, Martine Piccart-Gebhart, Gabriel N. Hortobagyi, Christine Desmedt, Lajos Pusztai, Benjamin Haibe-Kains, Cornelia Liedtke, William Fraser Symmans, Christos Hatzis, Vicente Valero
Publikováno v:
Journal of Clinical Oncology. 27:3185-3191
Purpose The genomic grade index (GGI) is a 97-gene measure of histological tumor grade. High GGI is associated with decreased relapse-free survival in patients receiving either endocrine or no systemic adjuvant therapy. Herein we examined whether GGI
Autor:
Montserrat Muñoz, Miguel Gil, Grischa Wachsmann, Serafin Morales, Keyur Mehta, Mireia Margeli, Bahriye Aktas, Noelia Martínez, Eva Carrasco, Winfried Schoenegg, José A. García-Sáenz, Juan de la Haba-Rodriguez, Antonio Antón, Manuel Ramos, Gunter von Minckwitz, Sibylle Loibl, Ángel L Guerrero, Cornelia Liedtke, Miguel Martin
Purpose To test whether combining bevacizumab, an anti–vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET. Patients and Methods A multicenter, randomized, open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c175281b6dffbb23a7faa2abbc03c238
https://www.ncbi.nlm.nih.gov/pubmed/25691671
https://www.ncbi.nlm.nih.gov/pubmed/25691671
Autor:
Peter A. Fasching, Thomas Bachelot, Hans Wildiers, Francesco Cognetti, Richard Greil, Denise A. Yardley, V. Tassell, Xin Huang, Cornelia Liedtke, Rolf Kreienberg, Kenneth A. Kern, Elżbieta Starosławska, Manuel Ramos, Véronique Diéras, Olivier Capitain, Neville Davidson, Gilles Romieu, Maria Blasinska-Morawiec, Jolanda Paolini, John Crown, Wilson H. Miller, George Fountzilas
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(23)
Purpose Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances. This may be related to the ability of breast tumors to induce neoangiogenesis, even in the face of cytotoxic chemotherap